SOPHiA GENETICS (SOPH) Chairman Jurgi Sells $62K of Stock

Jurgi Camblong, Executive Chairman of SOPHiA GENETICS SA (NasdaqGS: SOPH), sold 8,500 shares valued at approximately $61,670.90 on October 12, 2026, according to a Form 4 filing with the SEC. This planned sale took place as the company's stock trades below its recent averages.

Inside Camblong's Trade

Camblong's sale involved 8,500 shares at an average price of $7.26. This transaction adds to his previous sales, which included a smaller sale of shares on June 25, 2026, valued at $7,826.10. His recent actions suggest a strategic approach to managing his holdings in the company.

Other Institutional Activity in SOPHiA GENETICS

In addition to Camblong's trade, several other institutional investors are holding significant positions in SOPHiA GENETICS. Generation Investment Management LLP holds 6,789,560 shares, valued at about $45,693,738. AIGH Capital Management LLC increased its stake by 1,977,097 shares to a total of 3,954,194 shares, worth approximately $26,611,725. Royce & Associates LP added 1,565,454 shares, bringing its total to 3,381,736 shares valued at around $22,759,083. Principal Financial Group, Inc. also grew its holdings by 955,031 shares, ending with 2,364,256 shares worth about $15,911,442.

SOPHiA GENETICS SA Stock Down 6.6%

As of October 16, 2026, SOPHiA GENETICS shares recently traded around $6.81, which is 14.3% below the 50-day moving average of $7.95. The stock is currently 24.2% below its 52-week high of $8.98 but remains 81.6% above its 52-week low of $3.75. Analysts have set a mean price target of $9.75, indicating potential upside from the recent trading levels.

Recent Earnings

SOPHiA GENETICS reported trailing twelve-month revenue of approximately $86.2 million. However, the company has faced challenges with a net margin of -93.9% and a return on equity of -101.2%. The next earnings report is scheduled for November 3, 2026, which will provide further insights into the company's financial health.

Insider Buying and Selling at SOPHiA GENETICS SA

On the same day as Camblong's sale, Chief Medical Officer Menu Philippe sold 5,000 shares at an average price of $7.26, totaling around $36,303. This planned sale indicates ongoing activity among the company's executives regarding their shareholdings.

Analysts Set New Price Targets

On October 12, 2026, HC Wainwright & Co. reiterated its Buy rating for SOPHiA GENETICS, maintaining a price target of $14.0. The firm had previously raised its target from $12.0 on August 5, 2026. The consensus among analysts is a strong buy, with a mean price target of $9.75 based on four analyst opinions.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare sector. It provides a platform that helps analyze data and generate insights from various diagnostic data sets. This focus on data-driven healthcare solutions makes the company's stock movements particularly interesting as it navigates market conditions.

Bottom Line

Investors should keep an eye on the upcoming earnings report on November 3, 2026, for updates on SOPHiA GENETICS' performance. With ongoing insider activity and analyst support, the company's future actions may provide further insights into its strategic direction.